Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

46 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Assessing incidence and economic burden of genital warts with data from a US commercially insured population.
Hoy T, Singhal PK, Willey VJ, Insinga RP. Hoy T, et al. Among authors: insinga rp. Curr Med Res Opin. 2009 Oct;25(10):2343-51. doi: 10.1185/03007990903136378. Curr Med Res Opin. 2009. PMID: 19650749
Five-year routine cervical cancer screening rates and intervals in a US health plan.
Schabert VF, Ye X, Insinga RP, Singhal PK, Riedel AA. Schabert VF, et al. Among authors: insinga rp. Curr Med Res Opin. 2008 Sep;24(9):2429-35. doi: 10.1185/03007990802281671. Epub 2008 Jul 24. Curr Med Res Opin. 2008. PMID: 18662493
Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population.
Henk HJ, Insinga RP, Singhal PK, Darkow T. Henk HJ, et al. Among authors: insinga rp. J Low Genit Tract Dis. 2010 Jan;14(1):29-36. doi: 10.1097/LGT.0b013e3181ac05e9. J Low Genit Tract Dis. 2010. PMID: 20040833
Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans.
White RR, Lenhart G, Singhal PK, Insinga RP, Itzler RF, Pellissier JM, Segraves AW. White RR, et al. Among authors: insinga rp. Pharmacoeconomics. 2009;27(9):781-92. doi: 10.2165/11317560-000000000-00000. Pharmacoeconomics. 2009. PMID: 19757871
The health and economic burden of genital warts in a set of private health plans in the United States.
Insinga RP, Dasbach EJ, Myers ER. Insinga RP, et al. Clin Infect Dis. 2003 Jun 1;36(11):1397-403. doi: 10.1086/375074. Epub 2003 May 19. Clin Infect Dis. 2003. PMID: 12766834
Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans.
Insinga RP, Itzler RF, Pellissier JM. Insinga RP, et al. Pharmacoeconomics. 2007;25(2):155-69. doi: 10.2165/00019053-200725020-00007. Pharmacoeconomics. 2007. PMID: 17249857
The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.
Dasbach EJ, Insinga RP, Elbasha EH. Dasbach EJ, et al. Among authors: insinga rp. BJOG. 2008 Jul;115(8):947-56. doi: 10.1111/j.1471-0528.2008.01743.x. Epub 2008 May 22. BJOG. 2008. PMID: 18503574
Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.
Insinga RP, Dasbach EJ, Elbasha EH. Insinga RP, et al. Pharmacoeconomics. 2005;23(11):1107-22. doi: 10.2165/00019053-200523110-00004. Pharmacoeconomics. 2005. PMID: 16277547 Review.
Annual productivity costs due to cervical cancer mortality in the United States.
Insinga RP. Insinga RP. Womens Health Issues. 2006 Sep-Oct;16(5):236-42. doi: 10.1016/j.whi.2006.06.005. Womens Health Issues. 2006. PMID: 17055376
Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation.
Insinga RP, Dasbach EJ, Allen SE, Carides GW, Myers ER. Insinga RP, et al. Value Health. 2008 Dec;11(7):1022-32. doi: 10.1111/j.1524-4733.2008.00342.x. Epub 2008 May 16. Value Health. 2008. PMID: 18489503 Clinical Trial.
46 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback